|Author||: Sandro Matosevic|
|Publisher||: Academic Press|
|Release Date||: 2021-01-29|
|ISBN 10||: 9780128206270|
|Pages||: 200 pages|
Breaking Tolerance to Unresponsiveness to Immunotherapy by Natural Killer Cells presents chapters by leaders in translational natural killer cell research and bridges the gap between clinical need and basic science by presenting state-of-the-art knowledge on innate immunity and the challenges associated with translating it to practical adoptive immunotherapies. New approaches, such as the genetic engineering of NK cells and their combination with checkpoint blockade therapies are discussed among other potential interventions to improve natural killer cell functionality against targets. In addition, challenges, such as the difficulty in genetically modifying NK cells or a poor understanding of their effect on checkpoint inhibition are included. The book is a key reference and go-to resource for researchers and clinicians who want to understand the current limitations associated with bringing natural killer cell-based immunotherapies to the clinic. Discusses translational aspects from leaders in the field to facilitate readers' understanding of clinical challenges Addresses important events that occur in patient tumor microenvironments as they pertain to NK cells and how they are, or can be, tackled to overcome immunosuppression of NK cells Focuses on immunometabolism by discussing the metabolic reprogramming that NK cells undergo in solid tumors, including hypoxia, adenosine and other metabolites
|Author||: Jorge Morales-Montor,Mariana Segovia-Mendoza|
|Publisher||: Academic Press|
|Release Date||: 2020-10-14|
|ISBN 10||: 0128220295|
|Pages||: 286 pages|
Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interactions of different immune drugs, with an aim of offering researchers and clinicians cutting-edge therapies to overcome drug resistance. The book explains the latest immunotherapies for different types of cancer, helping users carry out research projects or create alternatives for drug development in the pharmaceutical industry. Topics discussed include the relationship between immunotherapy and macrophages, immune checkpoints in different types of cancer, immune cocktails in solid tumors, and immune-phenotyping. Additionally, the book presents basic and clinical data on immunoresistance and glycosylation. This book is a valuable source for cancer researchers, medical doctors, clinicians and members of the biomedical field who must understand certain mechanisms to fight cancer that is resistant to immunotherapy. Provides basic and clinical evidence based on molecular interactions and clinical studies to address the risks and benefits of cancer immunotherapy Presents the results of new immunotherapy trials, discussing the state-of-the-art in different types of cancer Discusses targeted therapies approved by the FDA, along with therapies with clinical potential used in basic studies
|Publisher||: Academic Press|
|Release Date||: 2019-10-04|
|ISBN 10||: 0128178698|
|Pages||: 376 pages|
Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic. The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance. This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites. Provides key scientific background for clinicians when developing novel clinical trials and important examples for basic scientists of the types of work required to move a concept from the lab to the clinic Presents consistent pathway diagrams in each chapter, thus making it easier to understand complicated pathways Includes chapter summaries of the critical next steps needed to move studies from their current state into practice changing clinical data
Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.
This reference brings together all aspects of renal cell carcinoma, and provides a basis for understanding the disease's origin, progression and responses to immunotherapy.;Examining the current status of cytokine, cell-based and chemotherapeutic methods of treatment, this book: discusses the clinical presentation of advanced renal carcinoma and its therapeutic challenges; reviews prognostic factors and the management of renal cell carcinoma occurring with von Hippel-Landau syndrome; summarizes efforts to identify the tumour suppressor gene deleted from chromosome 3 in most renal cell carcinomas; explicates the role of oncogenes in the progression of renal cell cancer and the molecular correlates of responses to interferon-alpha treatment; details the latest laboratory efforts to establish gene therapy for tumour treatment by transfection of cytokine genes in murine model systems; focuses on biologic response modifier therapy in humans, including cell-mediated immune responses and adoptive immunotherapy; presents preclinical and clinical studies of interleukin-2 alone, in combination with othe cytokines, and with chemothrapeutic agents; and addresses studies on the tumour necrosis factor and low- and high-dose interferon-alpha.
In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field.
Since the First Edition of The Autoimmune Diseases was published in 1985, interest as well as knowledge about autoimmune diseases has greatly increased. This edition incorporates new material and combines the basic aspects of autoimmunity with discussion of specific autoimmune diseases in humans. It discusses the biological basis of disease at genetic, molecular, cellular, and epidemiologic levels. In addition to a comprehensive discussion of various autoimmune diseases and organ systems, the editors also cover the role of autoimmunity in cancer, AIDS, and aging. Key Features * Provides comprehensive discussions of all autoimmune diseases and organ systems * Offers "bench to bedside" coverage of autoimmunity for both clinicians and research scientists * Discusses the biological basis of disease at genetic, molecular, cellular, and epidemiologic levels * Examines the environmental determinants of autoimmune disease * Examines the association between autoimmunity and aging, cancer, and AIDS
|Author||: Andrew Freywald,Franco Vizeacoumar|
|Publisher||: Academic Press|
|Release Date||: 2020-12-04|
|ISBN 10||: 0128213116|
|Pages||: 308 pages|
Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies
Leukocyte culture conferences have a long pedigree. This volume records some of the scientific highlights of the 16th such annual con ference, and is a witness to the continuing evolution and popularity of leukocyte culture and of immunology. There is strong evidence of the widening horizons of immunology, both technically, with the obviously major impact of molecular biology into our understanding of cellular processes, and also conceptually. Traditionally, the 'proceedings' of these conferences have been published. But have the books produced really recorded the major part of the conference, the informal, friendly, but intense and some times heated exchanges that take place between workers in tackling very similar problems and systems and which are at the heart of every successful conference? Unfortunately this essence cannot be incorpo rated by soliciting manuscripts. For this reason, we have changed the format of publication, retaining published versions of the symposium papers, but requesting the workshop chairmen to produce a summary of the major new observations and areas of controversy highlighted in their sessions, as a vehicle for defining current areas of interest and debate. Not an easy task, as the workshop topics were culled from the abstracts submitted by the participants, rather than being on predefined topics. The unseasonal warmth in Cambridge was reflected in the atmos phere of the conference, the organization of which benefited from the administrative skills of Jean Bacon, Philippa Wells, Mr. Peter Irving, and Mrs.
This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted. With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival.
The evidence of cancer in humans, animals and plant species suggests that it is as old as multicellular life on Earth. Why is it so difficult to understand and fight? Because cancer begins from the organism's own mutated single cell focused on its own survival. It would be naive to expect that cancer could be ever entirely eliminated, but there is still hope for finding effective treatments. The book is to give a view of selected aspects of cancer like its spread in nature, novel anticancer drugs based on Chinese herbs or birch bark, novel promising targets of annexins and kinases and progress in immunotherapy. It is our hope that you will find in this book interesting, inspiring and stimulating information concerning cancer research.
Medicine has entered a golden age in which therapeutic agents are becoming widely available due to advances in basic science and technology. As such, many drugs have been developed that target inflammatory processes and/or the immune system. This book is intended for health professionals examining the modulation of inflammation by immunotherapeutic drugs. The immune system fills the primordial role of host defense and resistance to infections with pathogenic microorganisms. Several hematopoietic-derived cells constituting the innate and adaptive immune systems cooperate to provide barriers for microbial colonization and/or promote pathogen destruction within the host. Conversely, many immune cells are also involved in the pathogenesis and propagation of chronic inflammatory diseases. The beginning of this book details various components of the immune system including the cell types, lymphoid tissues, soluble cytokines and surface molecules that are essential for host defense. Breakdowns in immune tolerance, or dysregulated immune responses to antigens derived from self tissues or innocuous sources, can lead to the development of autoimmunity or chronic inflammatory diseases. Pathophysiologic roles for the immune system are detailed in corresponding chapters on autoimmunity, epithelial surfaces (lungs, skin, intestine), and transplantation, with special emphasis placed on immunotherapeutic drug targets. The last section of the book focuses on treatments that stimulate our immune system to specifically target and fight infectious diseases and cancer. In each chapter, the medications used to treat various diseases/conditions in terms of their mechanism of action and other pharmacologic properties are detailed. Chapters begin with a table showing drug names and classifications. The importance of basic science and clinical trials cannot be understated in the context of drug development. As such, the discovery of certain medications that had a lasting impact in medicine and pharmacy are highlighted in chapter subsections named “Bench to Bedside.” Several clinical applications of immunotherapeutic drugs are described within end-of -chapter case studies including practice questions. The Pharmacology of Immunotherapeutic Drugs is a reference for immunologists and clinicians (medical doctors, pharmacists, nurses) examining the modulation of inflammatory processes by a variety of medications targeting the cells and mediators of our immune system.
|Author||: Pooja Jain|
|Publisher||: Springer Nature|
|ISBN 10||: 3030339467|
|Pages||: 329 pages|
In Natural Killer Cell Protocols: Cellular and Molecular Methods, Kerry S. Campbell and Marco Colonna have assembled a comprehensive collection of readily reproducible methods designed to study natural killer (NK) cells from the broadest variety of viewpoints. These include not only classic techniques, but also new approaches to standard methods, newly evolved techniques that have become valuable for specific applications, and unique models for manipulating and studying NK cells. Among the advanced methods covered are those for in vitro transendothelial migration, in vivo detection of cells migrating into tumors, immunofluorescence staining of intracellular cytokines, and in vitro NK cell development. Valuable techniques for specific applications include vaccinia virus protein expression, soluble KIR-Fc fusions for HLA class I binding assays, calcium mobilization in cell conjugates, and identification of heterodimeric receptor complexes using cDNA library expression cloning. No less important are accounts of such classic methods as hybrid resistance, ADCC, viral defense, target cell cytotoxicity assays, cloning and culturing, tumor immunotherapy, and generation of HLA class I transfected target cells. Natural Killer Cell Protocols: Cellular and Molecular Methods offers immunologists, cancer researchers, virologists, and cell biologists today's most comprehensive collection of both established and cutting-edge techniques, methods that will contribute significantly to advancing our understanding of this fascinating and critically important class of cells.
This updated 2nd edition provides a thorough grounding on the immune response, its diagnosis and its modification by drugs and chemicals. The first section of the book offers a basic introduction to immunology, updated to accommodate new immunological concepts. The second section on immunodiagnostics has been expanded to describe widely used molecular techniques and is followed by a systematic review of drugs affecting the immune system, revised to cover recent developments. The book concludes with a chapter on immunotoxicology. New aids to readers include a two-column format, glossaries of technical terms and appendix reference tables. The emphasis on illustrations is maintained from the first edition.
The book Immune Response Activation is aiming to analyse the multifaceted aspects of the immune response, treating a number of representative cases in which the immune response is, on one hand, activated against pathogens, and, on the other hand, involved in pathologic settings, leading to allograft rejection, allergy and autoimmunity. The regulatory mechanisms in which the immune response can be modulated for rendering its effector components more efficient and/or not harmful to the organism is also dissected in translational purposes in cancer immunotherapy, local immunity against bacteria and viruses, as well as in allergy and autoimmunity.
We are in constant search for new therapeutic options to cure cancer. In this book, you can find out how scientists throughout the world deal with this problem. Readers will learn how to engage nature, chemical synthesis, and cell machinery to design new anticancer agents. Nature has already been very generous in providing us different compounds which are in widespread application. Starting from these resources, various synthetic processes are applied to create synthetic drugs which can be then obtained in large quantities. Also, the cell by itself provides different possibilities to meet the constantly increasing requirements for successful therapy. Explore the book and find out what are the new ways to fight cancer.